Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta‐analysis
Abstract Introduction Several studies have investigated the efficacy of human urinary kallidinogenase (HUK) combined with edaravone (Eda) in acute ischemic stroke (AIS) patients. Our aim was to provide the best available evidence for clinical practice and further research programs for stroke treatme...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-12-01
|
| Series: | Brain and Behavior |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/brb3.2431 |
| _version_ | 1797754649545015296 |
|---|---|
| author | Di‐Xiao Yang Yao Li Dan Yu Bi Guan Qian Ming Yan Li Li‐Qing Chen |
| author_facet | Di‐Xiao Yang Yao Li Dan Yu Bi Guan Qian Ming Yan Li Li‐Qing Chen |
| author_sort | Di‐Xiao Yang |
| collection | DOAJ |
| description | Abstract Introduction Several studies have investigated the efficacy of human urinary kallidinogenase (HUK) combined with edaravone (Eda) in acute ischemic stroke (AIS) patients. Our aim was to provide the best available evidence for clinical practice and further research programs for stroke treatment. Methods We searched the online database for paper published between January 2015 and April 2021. We calculated weighted mean difference (WMD) or odds risk (OR) and their corresponding 95% confidence interval (95% CI) of reported outcomes between HUK plus Eda and Eda groups for each study. The random‐effect models or fixed‐effect models were used to pool the analysis. Results Thirteen studies with 1242 patients were included. In the pooled analysis, the scores of NIHSS in the HUK plus Eda group were significantly lower than that in patients receiving Eda (WMD = –3.92, 95% CI (–4.82, –3.02), p < .0001). The ADL scores in the HUK plus Eda group were significantly greater than that in patients receiving Eda (WMD = 14.13, 95% CI (10.67, 17.60), p < .0001). Furthermore, HUK plus Eda was associated with a higher rate of total efficacy (OR = 3.97, 95% CI (2.81, 5.59), p < .0001). Conclusions HUK combined with Eda provides potential clinical benefits as a treatment for AIS. Further high‐quality, large‐scale randomized trials are needed to confirm these results. |
| first_indexed | 2024-03-12T17:36:37Z |
| format | Article |
| id | doaj.art-525714f16f164324bdd7c93bfb55ce80 |
| institution | Directory Open Access Journal |
| issn | 2162-3279 |
| language | English |
| last_indexed | 2024-03-12T17:36:37Z |
| publishDate | 2021-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Brain and Behavior |
| spelling | doaj.art-525714f16f164324bdd7c93bfb55ce802023-08-04T10:55:54ZengWileyBrain and Behavior2162-32792021-12-011112n/an/a10.1002/brb3.2431Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta‐analysisDi‐Xiao Yang0Yao Li1Dan Yu2Bi Guan3Qian Ming4Yan Li5Li‐Qing Chen6Department of Nursing Administration Chengdu Fifth People's Hospital Chengdu ChinaIntensive Care Unit Chengdu Fifth People's Hospital Chengdu ChinaDepartment of Otorhinolaryngologic Chengdu Fifth People's Hospital Chengdu ChinaDepartment of Nursing Administration Chengdu Fifth People's Hospital Chengdu ChinaDepartment of Nursing Administration Chengdu Fifth People's Hospital Chengdu ChinaDepartment of Nursing Administration Chengdu Fifth People's Hospital Chengdu ChinaDepartment of Otorhinolaryngologic Chengdu Fifth People's Hospital Chengdu ChinaAbstract Introduction Several studies have investigated the efficacy of human urinary kallidinogenase (HUK) combined with edaravone (Eda) in acute ischemic stroke (AIS) patients. Our aim was to provide the best available evidence for clinical practice and further research programs for stroke treatment. Methods We searched the online database for paper published between January 2015 and April 2021. We calculated weighted mean difference (WMD) or odds risk (OR) and their corresponding 95% confidence interval (95% CI) of reported outcomes between HUK plus Eda and Eda groups for each study. The random‐effect models or fixed‐effect models were used to pool the analysis. Results Thirteen studies with 1242 patients were included. In the pooled analysis, the scores of NIHSS in the HUK plus Eda group were significantly lower than that in patients receiving Eda (WMD = –3.92, 95% CI (–4.82, –3.02), p < .0001). The ADL scores in the HUK plus Eda group were significantly greater than that in patients receiving Eda (WMD = 14.13, 95% CI (10.67, 17.60), p < .0001). Furthermore, HUK plus Eda was associated with a higher rate of total efficacy (OR = 3.97, 95% CI (2.81, 5.59), p < .0001). Conclusions HUK combined with Eda provides potential clinical benefits as a treatment for AIS. Further high‐quality, large‐scale randomized trials are needed to confirm these results.https://doi.org/10.1002/brb3.2431acute ischemic strokeedaravonehuman urinary kallidinogenasemeta‐analysis |
| spellingShingle | Di‐Xiao Yang Yao Li Dan Yu Bi Guan Qian Ming Yan Li Li‐Qing Chen Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta‐analysis Brain and Behavior acute ischemic stroke edaravone human urinary kallidinogenase meta‐analysis |
| title | Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta‐analysis |
| title_full | Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta‐analysis |
| title_fullStr | Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta‐analysis |
| title_full_unstemmed | Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta‐analysis |
| title_short | Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta‐analysis |
| title_sort | human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients a meta analysis |
| topic | acute ischemic stroke edaravone human urinary kallidinogenase meta‐analysis |
| url | https://doi.org/10.1002/brb3.2431 |
| work_keys_str_mv | AT dixiaoyang humanurinarykallidinogenasecombinedwithedaravoneintreatingacuteischemicstrokepatientsametaanalysis AT yaoli humanurinarykallidinogenasecombinedwithedaravoneintreatingacuteischemicstrokepatientsametaanalysis AT danyu humanurinarykallidinogenasecombinedwithedaravoneintreatingacuteischemicstrokepatientsametaanalysis AT biguan humanurinarykallidinogenasecombinedwithedaravoneintreatingacuteischemicstrokepatientsametaanalysis AT qianming humanurinarykallidinogenasecombinedwithedaravoneintreatingacuteischemicstrokepatientsametaanalysis AT yanli humanurinarykallidinogenasecombinedwithedaravoneintreatingacuteischemicstrokepatientsametaanalysis AT liqingchen humanurinarykallidinogenasecombinedwithedaravoneintreatingacuteischemicstrokepatientsametaanalysis |